Oncologist focus on GI tumors. Biliary-pancreatic& gastroesophaguesl tumors in @hospitaldelmar @HMar_research.
Joined July 2011
- Tweets 6,568
- Following 710
- Followers 437
- Likes 4,554
97 Photos and videos
lvisa retweeted
Jun 10
Adjuvant Chemotherapy /- Chemoradiotherapy for Adenocarcinoma of The Pancreatic Head: Results of The Radiotherapy Randomization of NRG Oncology/RTOG 0848 | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
8
33
14,845
lvisa retweeted
Jun 10
Multidisciplinary Management of Esophageal Cancer | JCO Oncology Practice ascopubs.org/doi/abs/10.1200…
1
18
54
3,662
El ingeniero que creó claude code acaba de soltar un video de 28 minutos donde te enseña a escribir prompts que realmente funcionan.
He visto cursos de 300 dólares que no llegan ni a la mitad de lo que explica en los primeros 10 minutos.
Archivos CLAUDE.md, atajos de memoria, sesiones paralelas y patrones de prompting que cambian el juego.
Todo en un solo video y completamente gratis.
Da igual si eres desarrollador, principiante o ya llevas meses usando Claude. Esto te va a volar la cabeza.
126
2,704
15,748
1,763,715
lvisa retweeted
Jun 5
Daraxonrasib #PancreaticCancer data is a major step, but skin toxicity limits dosing.
Timely 4-step algorithm in @OncJournal protects patient QoL & treatment continuity.
academic.oup.com/oncolo/adva…
#OncoTwitter #PancreaticCancer #Oncology #SupportiveCare
ALT https://academic.oup.com/oncolo/advance-article/doi/10.1093/oncolo/oyag194/8699602
4
22
40
4,741
lvisa retweeted
📢New publication from our group in collab with @Nb4Diagnostics! We report the 1st quantitative LFIA for detecting soluble AXL (sAXL) in plasma as a potential biomarker for PDAC diagnosis. Congrats to all the researchers involved, especially the 1st author @nuriavazquezbe👏
1
1
7
147
lvisa retweeted
👩🔬L'equip de recerca de l'@IQAC_CSIC, l'@iibbcsic i l'@hmar_research #HMRIB desenvolupen un test capaç de detectar el biomarcador sAXL del càncer de pàncrees en minuts amb una mostra de sang🩸.
👉Més info: hospitaldelmar.cat/ca/notici…
@CSIC #CàncerdePàncrees #Recerca
1
3
167
lvisa retweeted
👩🔬El equipo de investigación de @iqac_csic, @iibbcsic y @hmar_research #HMRIB desarrollan un test capaz de detectar el biomarcador sAXL del cáncer de páncreas en minutos con una muestra de sangre🩸.
👉Más info: hospitaldelmar.cat/es/notici…
@csic #CàncerdePàncrees #Investigación
3
5
385
lvisa retweeted
May 31
Mutluluk, başınıza gelenlerin bir sonucu değil, başınıza gelenleri nasıl yorumladığınızın ve onlara nasıl tepki verdiğinizin bir sonucudur.
34
603
6,647
1,218,003
lvisa retweeted
With all the excitement around daraxonrasib, I needed to refresh my RAS inhibitor knowledge, so here we go:
11
155
729
87,037
Toda la Plenaria de #ASCO26, en pie para aplaudir el trabajo que cambia la práctica clínica en cáncer de páncreas. Investigación para mejorar la supervivencia de los pacientes oncológicos 🙌🏻🙌🏻🙌🏻
📹 @Tony_Calles
‼️ La mejor noticia para los pacientes con cáncer de páncreas metastásico. Una nueva terapia dirigida duplica la supervivencia. Impactantes resultados. Es el inicio de una revolución, la de los inhibidores de RAS. El estudio fase III RASolute 302 se está presentando hoy en #ASCO26, el Congreso de Oncología Médica más importante del mundo.
1
63
181
36,396
lvisa retweeted
Beautiful discussion by #DrJenniferKnox
👉New standard of care, at last!
🫂Delay in QoL worsening
🧴Skin toxicity - we need dermatology friends
🤝We must work together: researchers, pharma, patients and regulatory agencies
🔮Many trials - 1stL/adjuvant
@myESMO @ASCO @AACR
31 May 2026, Chicago
Full #HallB1 at @ASCO #ASCO26
#Daraxonrasib doubles both #OS and #PFS for advanced #PDAC - paradigm change
I feel honoured to be in this room today 🙌🏻
🔬Science means hope🧬
And this bit of hope goes to #PDAC💜
🗓️Now: access 💪
@P_C_E_ @ACanPan @myESMO
8
33
2,140
lvisa retweeted
Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer
Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived
#ASCO26
92
1,273
6,504
1,151,855
May 31
Historic moment in pancreatic cancer.
RASolute 302 is practice-changing. Now we need fast regulatory approval and patient access in Europe, Spain and Catalonia. @hospitaldelmar @PNavarro_Lab @SCPancrees @letswinpc @ACanPan #ASCO26 #PancreaticCancer#SEOM
Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer
Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived
#ASCO26
2
8
607
lvisa retweeted
May 31
👏Standing ovations for Daraxonrasib👏
Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic cancer: Primary and final analysis from the phase-3 RASolute 302 study
👉mPFS 7.6 vs 3.5 mo
👉mOS: 13.2 vs 6.6 mo
👏Fantastic news, new standard of care
@myesmo @ASCO
1
25
82
2,558
lvisa retweeted
May 31
The overall survival curves for Daraxonrasib in 2nd line advanced #PancreaticCancer leave no doubt how impactful this advance is for the field & for patients. Congratulations Brian Wolpin, @EileenMOReilly & @md_oberstein et al.
A seminal #ASCO26 plenary!
nejm.org/doi/full/10.1056/NE…
2
64
200
14,331
lvisa retweeted
Targeting claudins in cancer nature.com/articles/s41573-0… rdcu.be/flf2S
Claudins, which are key regulators of epithelial function, are emerging as targets in cancer, validated by the approval of a CLDN18.2-targeted drug. This new Review discusses progress in the area #ASCO26
31
87
8,721
lvisa retweeted
May 31
🎯Claudin18.2 targeting in pancreatic cancer
#ASCO26
➡️First line, claudin18.2/cd3 bispecific ab GnP
✅ORR: 59.8%
✅mPFS: 8.7 mo, mOS: 15.8 mo
#cancer #oncology #MedX #pancreatic #GI @OncoAlert
14
30
1,363
lvisa retweeted
For readers interested in bispecific antibodies in oncology, here's a review #ASCO26
nature.com/articles/s41573-0…
rdcu.be/flJDG
61
183
13,528
Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM
@ASCO
ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.
52
2,055
5,577
2,470,811
lvisa retweeted
May 31
🚀Daraxonrasib curves @NEJM 👇
2L of metastatic pancreatic cancer
#ASCO26
nejm.org/doi/full/10.1056/NE…
#cancer #oncology #pancreatic #MedX @OncoAlert @realbowtiedoc @DrVilmaPBarcia
1
28
59
2,594